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ABSTRACT
Background: In chronic liver diseases, a correct estimation of the severity of liver fibro-
sis is important for recommendations regarding the treatment. Nowadays, evaluation 
of fibrosis is done by noninvasive methods such as biochemical scores and transient 
elastography instead of liver biopsy. The lack of sensitivity to detect fibrosis, because 
of its heterogeneity is a drawback of liver biopsy (LB).
Objectives: To compare transient elastography (TE) and acoustic radiation force im-
pulse (ARFI) for the evaluation of liver stiffness (LS), against percutaneous LB.
Patients and Methods: Our study comprised of 223 subjects; 52 without fibrosis (38 
volunteers and 14 patients with F0 on LB), 36 with F1, 40 with F2, 26 with F3 and 69 
with liver cirrhosis (46 with LB and 23 with signs of cirrhosis). For each patient we 
performed in the same session 10 TE and 5 ARFI measurements. The median values 
were calculated.
Results: A strong linear correlation (Spearman rho = 0.870) was found between TE and 
fibrosis (P < 0.0001); there was also a weaker correlation between ARFI and fibrosis 
(Spearman rho = 0.646; P < 0.0001). TE measurements were also correlated with ARFI 
measurements (Spearman rho = 0.733, P < 0.0001). The best test for predicting sig-
nificant fibrosis (F ≥ 2) was TE with a cut-off value of 7.1 kPa (AUROC 0.953). For ARFI, 
the cut-off value was 1.27 m/s—area under ROC curve (AUROC): 0.890, sensitivity (Se) 
of 88.7%, specificity (Sp) of 67.5%, positive predictive value (PPV) of 64.5%, and negative 
predictive value (NPV) of 90% (P = 0.0044). For predicting cirrhosis (F = 4), the opti-
mum cut-off values were 14.4 kPa for TE (AUROC: 0.985, Se: 95.6%, Sp: 94.7%, PPV: 89.2%, 
NPV: 98%) and 1.7 m/s for ARFI (AUROC: 0.931, Se: 93%, Sp: 86.7%, PPV: 73.6%, NPV: 96.9%) 
(P = 0.0102).
Conclusions: LS evaluation by means of ARFI is not superior to TE for the assessment of 
liver fibrosis. ARFI is an accurate test for the diagnosis of cirrhosis.
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1. Background
In  chronic  liver  diseases  a  correct  estimation 
of  the  severity  of  liver  fibrosis  is  important  for 
recommendations regarding the treatment (especially 
in  chronic  viral  hepatitis),  for  prognosis  and  follow-
up. Until a few years ago, the evaluation of fibrosis (1) 
was made only by means of liver biopsy (LB)—the gold 
standard technique for evaluation of activity and fibrosis, 
but later on, non-invasive methods such as biochemical 
scores  and  transient  elastography  (TE)  emerged  (2,  3). 
A major disadvantage of LB is its invasiveness: the risk 
of post-biopsy discomfort for patients and sometimes, 
for its serious complications (4-7). Lack of sensitivity to 
detect fibrosis, because of its heterogeneity (8), is also 
a  drawback  for  LB.  A  biopsy  specimen  at  least  15  mm 
long is needed (9) for a proper histological assessment. 
Methods  of  liver  fibrosis  evaluation  using  ultrasound 
waves include TE (FibroScan) (10-12), sonoelastography 
(real-time tissue elastography) (RT-E) (13-17) and acoustic 
radiation force impulse elastography (ARFI) (18-21). They 
are  noninvasive  methods,  well  tolerated  by  patients, 
and rapid. Another advantage of ARFI and RT-E is that 
the technologies are incorporated into a conventional 
ultrasound  system.  However,  their  value  is  still  under 
evaluation.  Transient  elastography  is  an  ultrasound-
based method. By using an ultrasound transducer probe 
mounted  on  the  axis  of  a  vibrator,  the  transmission 
of low frequency vibrations from the right intercostal 
space  creates  an  elastic  shear  wave  that  propagates 
into  the  liver.  A  pulse-echo  ultrasound  acquisition  is 
then  used  to  detect  the  velocity  of  wave  propagation. 
This velocity is proportional to the tissue stiffness, with 
faster wave progression occurring through stiffer parts. 
LS  measurement  is  then  performed  and  the  result  is 
measured in kPa (11). The disadvantages of the method 
are that the device is performing only elastography, that 
measurements  cannot  be  performed  in  patients  with 
ascites, and that sometimes, valid measurements cannot 
be made for instance in patients with lack of acoustic 
window (i.e., in obese patients). Sono-elastography from 
Siemens, a very new method still under evaluation, uses 
a  different  technology.  The  system  enables  qualitative 
visual  and/or  quantitative  measurements  of  the 
mechanical  stiffness  properties  of  the  tissue.  Virtual 
Touch™  tissue  imaging  application  implements  ARFI 
technology  for  the  evaluation  of  deep  tissues,  not 
accessible  to  superficial  compression  elastography 
techniques.  Using  image-based  localization  and  a 
proprietary implementation of ARFI technology, shear 
wave speed may be quantified in a precise anatomical 
region, focused on a region of interest, with a predefined 
size,  provided  by  the  system.  Measurement  value  and 
depth are also reported; the results of the elasticity are 
reported in m/s. The advantages of the method are that 
it  is  incorporated  in  an  ultrasound  machine,  that  the 
operator can choose the place of measurement under 
direct ultrasound guidance, and that the examination 
can be also performed in patients with ascites.
2. Objectives
The aim of our study was to compare two noninvasive 
methods for the evaluation of liver fibrosis: TE and ARFI, 
in patients with diffuse chronic liver diseases.
3. Patients and Methods
Our  study  was  performed  in  Timisoara  and  Cluj.  It 
included 223 patients—38 healthy volunteers, 162 patients 
with chronic liver diseases confirmed by LB and 23 with 
clinical,  ultrasonographic  and/or  endoscopic  signs  of 
cirrhosis. The healthy volunteers were medical students, 
nurses and physicians from our hospital. None of them 
had a history of liver disease (acute or chronic). We did 
not  perform  additional  tests  in  this  subgroup  (such 
as  biological  tests,  viral  hepatitis  markers,  abdominal 
ultrasound).  However,  we  performed  abdominal 
ultrasound  in  all  patients  included  in  the  study,  just 
before the elastographic measurements and noted the 
presence of liver steatosis and splenomegaly. None of the 
healthy volunteers had steatosis or splenomegaly. In the 
subgroup of 23 cirrhotic patients, the diagnosis was made 
based  on  clinical  criteria,  ultrasound,  endoscopy,  and 
LB. None had ascites at the moment of evaluation. They 
were all considered as F4 in the Metavir scoring system 
and they were all Child-Pugh A or B. We excluded patients 
with liver cirrhosis and ascites due to the fact that even if 
ARFI can be performed in patients with ascites, TE is not 
feasible in this group of patients. Liver stiffness (LS) was 
determined in each patient by TE (FibroScan®, EchoSens) 
and ARFI (Siemens Acuson S2000TM ultrasound system) 
in the same session. The LB should had been performed 
within six months before entering the study; none of the 
patients had received antiviral therapy. All the patients 
agreed to participate in this study. The study protocol 
was approved by the local Ethics Committee.
3.1. Transient elastography
TE was performed in all patients with a FibroScan® device 
(Echosens®,  Paris,  France)  by  experienced  physicians 
(more than 1,000 examinations each). In each patient, 10 
valid measurements were made; then, median of LS was 
calculated and reported in kPa. Only patients in whom LS 
measurements had a success rate (SR) of at least 60% and 
with an interquartile range (IQR) of less than 30% were 
included in our study.
3.2. Acoustic radiation force impulse elastography
This  new  type  of  probe  automatically  generates  a 
pressure wave that propagates into the liver. Its speed, 
measured  in  m/s,  is  displayed  on  the  screen.  The 
propagation speed increases with fibrosis. The operator 
can  select  the  depth  at  which  the  liver  elasticity  is 
evaluated, by placing a “measuring box” (10 mm long Hepat Mon. 2011;11(7):532-538
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and 5 mm wide) in the desired place. In all our patients, 
Virtual  Touch  tissue  quantification  was  performed, 
using the new Siemens Acuson S2000. The patients were 
examined in left lateral decubitus position with the right 
arm in maximum abduction. Scanning was performed 
between the ribs in the right liver lobe (to mask cardiac 
motion),  with  minimal  scan  pressure  applied  by  the 
operator, while the patients were asked to stop breathing 
for  a  moment  to  minimize  breathing  motion.  We 
performed five valid measurements in every patient; a 
median value was calculated; the result was reported in 
m/s. In 111 patients from Timisoara, ARFI measurements 
were made in three points: sub-capsular (0–1 cm), 1–2 cm 
and 2–3 cm under the capsule, and a median value was 
calculated and reported in m/s, trying to find out the best 
point to measure liver elasticity. We were able to perform 
measurements in the sub-capsular area in all 111 patients, 
but only in 95.5% (106 cases) of them at 1–2 cm below the 
capsule and in 85.6% (95 cases) of them at 2–3 cm below 
the capsule.
3.3. Liver biopsy
LB  was  performed  in  112  patients  using  the  TruCut 
technique with a 14G (1.8 mm in diameter) automatic 
needle  device,  Biopty  Gun  (Bard  GMBh).  Fifty  patients 
underwent  echo-assisted  LB  using  Menghini  type 
modified  needles,  1.4  and  1.6  mm  in  diameter.  Only 
LB  fragments  including  at  least  six  portal  tracts  were 
considered adequate for pathological interpretation and 
included in our study. The LBs were assessed according 
to the Metavir score by two senior pathologists. Fibrosis 
was staged on a 0–4 scale according to the Metavir score 
(22, 23): F0: no fibrosis; F1: portal fibrosis without septa; 
F2: portal fibrosis and few septa extending into lobules; 
F3: numerous septa extending to adjacent portal tracts 
or terminal hepatic venules and F4: cirrhosis. All the LBs 
were performed in patients with HCV chronic hepatitis 
for the accurate staging and grading of the liver disease.
3.4. Statistical analysis
Data  were  entered  into  a  Microsoft  Excel  sheet.  The 
analyses were done by SPSS. All the predictors for the 
stage  of  fibrosis  (TE  and  ARFI  measurements)  were 
numeric variables, so the mean and standard deviation 
were calculated. Associations between assay results and 
fibrosis stage according to the Metavir scoring system 
(range:  0–4,  ordinal  scale)  were  described  using  the 
Fibrosis ARFI , m/s, No. (mean ± SD) TE , kPa, No. (mean ± SD)
0 52 (1.28 ± 0.43) 52 (4.46 ± 1.41)
1 34 (1.14 ± 0.3) 35 (5.68 ± 2.04)
2 34 (1.36 ± 0.47) 40 (9.11 ± 6.23)
3 23 (1.64 ± 0.51) 25 (10.39 ± 4.1)
4 57 (2.60 ± 0.70) 69 (37.88 ± 19.94)
Table 1. The mean value of liver elasticity assessed by TE and ARFI
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Spearman rank correlation coefficient (ρ). The diagnostic 
performances of the noninvasive tests were assessed by 
receiver  operating  characteristics  (ROC)  curves.  ROC 
curves were built for the detection of: significant fibrosis 
(F ≥ 2 Metavir) and cirrhosis (F ≥ 4). Optimal cut-off values 
were chosen to maximize the sum of sensitivity (Se) and 
specificity (Sp). Se and Sp were calculated according to 
standard  methods.  Exact  confidence  intervals  (CI)  of 
95% were calculated for each predictive test and used for 
comparing area under ROC (AUROC) curves.
4. Results
4.1. Patients
We studied 223 patients (90 men and 133 women with 
a mean ± SD age of 48 ± 13.05 years). The study sample 
included 52 subjects (23.3%) without fibrosis (38 healthy 
volunteers—considered F0 Metavir and 14 subjects with 
F0 on LB), 36 (16.1%) with F1, 40 (17.9%) with F2, 26 (11.7%) 
with  F3  (all  patients  underwent  LB)  and  69  (30.9%) 
patients  with  liver  cirrhosis  (46  with  LB  and  23  with 
clinical,  ultrasonographic  and/or  endoscopic  signs  of 
cirrhosis). The etiologies of cirrhosis in 69 patients were 
HCV infection in 59 (85.5%) cases, HBV infection in 2 (2.9%), 
alcohol abuse in 4 (5.8%) and primary biliary cirrhosis in 
another 4 (5.8%) cases. 
4.2. Histological fibrosis stage
From 162 patients for whom LB was performed, 14 (8.6%) 
had no fibrosis (F0), 36 (22.2%) had mild fibrosis (F1), 40 
(24.7%) had significant fibrosis (F2), 26 (16%) had severe 
fibrosis (F3), and 46 (28.4%) had cirrhosis (F4), according 
to the Metavir scoring system.
4.3. Liver stiffness measurements
From 223 subjects, valid LS measurements were made 
in 221 by TE, in 200 by ARFI and in 199 patients with both 
methods (there were invalid measurements in 10.8% of 
patients). LS measurements ranged from 2.3 to 75 kPa 
with TE and from 0.71 to 4.48 m/s with ARFI. A strong linear 
correlation (ρ = 0.870) was found between TE and fibrosis 
(P < 0.0001). A weaker correlation was found between 
ARFI and fibrosis (ρ = 0.646; P < 0.0001). TE measurements 
were also correlated with ARFI measurements (ρ = 0.733; 
P < 0.0001). The mean LS measurements according to the 
severity of fibrosis, assessed by TE and ARFI, are presented 
in Table 1 and Figure 1a and 1b. The best test for predicting 
significant fibrosis (F ≥ 2 Metavir) was TE with a cut-off 
value of 7.1 kPa (AUROC of 0.953, with a Se of 93.6%, Sp of 
78.7%, positive predictive value (PPV) of 76.5% and negative 
predictive value (NPV) of 94.3%). For ARFI, the cut-off value 
was 1.27 m/s (AUROC 0.890), with a Se of 88.7%, Sp of 67.5%, 
PPV of 64.5% and NPV of 90% (P = 0.0044) (Table 2; Figure 
2). For predicting cirrhosis (F = 4 Metavir), the optimum 
cut-off values were 14.4 kPa for TE (AUROC = 0.985, with 
a Se of 95.6%, Sp of 94.7 %, PPV of 89.2% and NPV of 98%) 
and 1.7 m/s for ARFI (AUROC = 0.931, with a Se of 93%, 
Sp of 86.7%, PPV of 73.6% and NPV of 96.9%) (P = 0.0102) 
(Table 2; Figure 3). Comparing the results in connection 
with the depth of ARFI measurements (111 subjects from 
Timisoara),  a  significant,  direct  correlation  was  found 
between ARFI (median value of 5 measurements made 1-2 
cm and 2-3 cm below the liver capsule) and the severity 
of  liver  fibrosis  (ρ  =  0.675  and  ρ  =  0.714,  respectively) 
(P  <  0.001).  The  subcapsular  measured  values  of  ARFI 
showed a poor correlation with fibrosis (ρ = 0.469). For 
ARFI, measurements made 1-2 cm and 2-3 cm below the 
liver capsule had the best predictive value for predicting 
significant  fibrosis  (F  ≥  2  Metavir),  with  AUROCs  not 
significantly different from each other (0.767 and 0.731, 
respectively, P = 0.264). For ARFI in connection with the 
depth of examination, the cut-off value was 1.4 m/s for 
measurements made 1-2 cm below the capsule, with a 
Se of 71% and Sp of 78% (AUROC = 0.767); the cut-off value 
was 1.26 m/s for measurements made 2-3 cm below the 
Figure 1. The mean value of liver elasticity assessed by TE (A) and ARFI (B)
(A) (B)Hepat Mon. 2011;11(7):532-538
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capsule, with a Se of 75% and Sp of 64% (AUROC = 0.731).
For predicting cirrhosis (F = 4 Metavir), the optimum 
cut-off values were 1.8 m/s for measurements made 1-2 
cm under the capsule (AUROC = 0.929) and 1.78 m/s for 
measurements made 2-3 cm under the capsule (AUROC 
= 0.951).
5. Discussion
The  correct  evaluation  of  liver  fibrosis  in  chronic 
diffuse hepatopathies is of paramount importance for 
the management of these diseases. LB is still considered 
the  gold  standard  for  the  assessment  of  severity  of 
fibrosis. Studies comparing the noninvasive methods of 
evaluation  in  chronic  liver  disease  with  LB  have  been 
conducted to assess whether they merit replacing this 
invasive method in the future. Considering the fact that 
fibrosis  is  heterogeneously  distributed  in  the  liver,  LB 
has been criticized in the past because it evaluates only 
1/50,000 of the total volume of the liver, due to the small 
volume of the tissue sample (7). It has been shown that 
liver  fragments  obtained  in  the  same  session  by 
laparoscopic biopsy from the left and right liver lobes 
revealed different stages of fibrosis in almost half of the 
patients (8). In 14.5% of the cases, cirrhosis was present in 
one of the lobes but not in the other and in 33.1% of the 
cases the stage of fibrosis was higher in one of the lobes 
by at least one point (8). By means of percutaneous LB, 
tissue samples 1-4 cm in length are obtained (preferably 
at least 1.5 cm) whatever the kind of needle used (4). Also, 
one must consider that the smaller the liver sample size 
is, the higher is the chance to subevaluate the severity of 
the liver disease (24, 25). Using a mathematical model, 
Bedossa (9) estimated that the chance of misdiagnosis 
in a fragment 2.5 cm in length can be as high as 25% and 
that the optimal size of a LB sample is 4 cm (difficult 
enough to obtain in daily practice). Also we must not 
forget that LB is an invasive method which would cause 
anxiety to the patient who has to undergo the procedure 
and that LB is not totally risk-free. Published data state 
that serious complications following diagnostic LB may 
occur in 1%–5% of the cases (5, 6) and, also, that the death 
rate following diagnostic LB can reach 1–3/10,000 of the 
biopsied cases (4, 7). On the other hand, TE assessment of 
LS was validated as a method of evaluation in chronic 
HCV hepatitis. Furthermore, there are some papers that 
proved  the  value  of  this  method  in  other  chronic 
hepatopathies  (such  as  HBV  chronic  infection, 
hemochromatosis,  primary  billiary  cirrhosis  or  non-
alcoholic steatohepatitis) (26-31). Two meta-analyses (11, 
27) demonstrated that this method is very good for the 
diagnosis of cirrhosis and advanced fibrosis. Even if our 
study may have a possible error factor, due to the fact 
that it included not only patients who had undergone 
LB  (considered  to  be  the  “gold  standard”  for 
hepathological  evaluation),  but  also  patients  who  did 
not have any known hepatic pathology (considered to 
be  “normal”),  as  well  as  patients  with  known  liver 
cirrhosis  (some  without  morphologic  exam),  it  seems 
that TE can be considered a reliable diagnostic modality 
for clinical practice. In our study, the optimum LS cut-off 
values for liver cirrhosis (F = 4 Metavir) were 14.4 kPa for 
TE (AUROC = 0.985, with a Se of 95.6%, Sp of 94.7 %, PPV of 
89.2%  and  NPV  of  98%)  and  1.7  m/s  for  ARFI  (AUROC  = 
0.931, with a Se of 93%, Sp of 86.7%, PPV of 73.6% and NPV 
of 96.9%), TE had a better predictive value (P = 0.0102). 
The  best  test  for  predicting  significant  fibrosis  (F  ≥  2 
Metavir)  was  again  TE,  with  a  cut-off  value  of  7.1  kPa 
(AUROC = 0.953, with a Se of 93.6%, Sp of 78.7%, PPV of 
76.5% and NPV of 94.3%). For ARFI, the cut-off value was 
1.27 m/s (AUROC = 0.890, with a Se of 88.7%, Sp of 67.5%, 
PPV  of  64.5%  and  NPV  of  90%)  (P  =  0.0044).  ARFI 
elastography  is  a  new  technology  available  on  the 
Siemens Acuson S2000 ultrasound system and its use is 
not well established yet. In a previous study performed 
by our group (21) ARFI was not superior to TE for the 
Figure 2. Comparative predictive values of LS measurements by TE and ARFI 
for prediction of significant fibrosis (F ≥ 2 Metavir)
F012 VS. F34
Figure 3. Comparative predictive values of LS measurements by TE and ARFI 
for prediction of cirrhosis (F = 4 Metavir)
F0123 VS. F4Hepat Mon. 2011;11(7):532-538
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assessment of liver fibrosis but was an accurate test for 
the diagnosis of cirrhosis. The present study aimed at 
validating  the  previous  results  on  a  larger  group  of 
patients. ARFI is a new method, still under evaluation so 
we tried to find the ideal place to measure liver elasticity 
(it is not specified by the producer). In all 111 subjects 
from  the  Timişoara  subgroup,  we  performed 
measurements in 3 points: subcapsular (0-1 cm below 
the liver capsule), at 1-2 cm under the capsule and at 2-3 
cm  under  the  capsule.  We  were  able  to  perform 
measurements in the subcapsular area in all 111 subjects 
who were evaluated by ARFI, but only in 95.5% (106 cases) 
of them at  1-2 cm below the capsule and in 85.6% (95 
cases)  of  them  at  2-3  cm  below  the  capsule.  The  best 
correlation with fibrosis was obtained for measurements 
made at 2-3 cm below the capsule (ρ = 0.714) and at 1-2 cm 
under the capsule (ρ = 0.675). Considering all these facts, 
probably the best place for ARFI determinations should 
be 1-2 cm below the capsule. In our study we found a 
linear correlation between ARFI and fibrosis (ρ = 0.646; P 
< 0.0001). TE measurements were also correlated with 
ARFI measurements (ρ = 0.733, P < 0.0001). For ARFI, the 
cut-off  value  for  predicting  significant  fibrosis  (F  ≥  2 
Metavir) was 1.27 m/s (AUROC = 0.890), with a Se of 88.7%, 
Sp of 67.5%, PPV of 64.5% and NPV of 90% (P = 0.0044). For 
predicting cirrhosis (F = 4 Metavir), the optimal cut-off 
value was 1.7 m/s for ARFI (AUROC = 0.931, with a Se of 
93%,  Sp  of  86.7%,  PPV  of  73.6%  and  NPV  of  96.9%)  (P  = 
0.0102). Several other studies evaluated the performance 
of this method (18-20, 32-35). In a study performed by 
Friedrich-Rust (18), in which ARFI was compared to LB 
and blood markers in 86 patients with chronic hepatitis 
(HBV  or  HCV),  the  Spearman  correlation  coefficients 
between  the  histological  fibrosis  stage  and  ARFI,  TE, 
FibroTest  and  APRI  scores,  indicated  significant 
correlations of 0.71, 0.73, 0.66, and 0.45, respectively (P < 
0.001). In the study performed by Lupşor and co-workers 
(19), 112 consecutive patients with chronic HCV hepatitis 
were evaluated through histology (Metavir score), ARFI 
and  TE.  In  this  study,  ARFI  was  correlated  with  liver 
fibrosis (r = 0.717, P < 0.0001) and necroinflammatory 
activity (r = 0.328, P < 0.014), but not with steatosis (r = 
0.122,  P  =  0.321).  In  this  study  there  was  a  significant 
increase in mean ± SD ARFI values in parallel with the 
increase in fibrosis stage as follows: 1.079 ± 0.150 m/s (F0-
F1), 1.504 ± 0.895 m/s (F2), 1.520 ± 0.575 m/s (F3), 2.552 ± 
0.782 m/s (F4) (P < 0.0001), but there was a certain degree 
of  overlap  between  the  consecutive  stages  F1-F2  (P  = 
0.072)  and  F2-F3  (P  =  0.965).  In  this  study  the  cut-off 
values predictive for each fibrosis stage were 1.19 m/s for 
F ≥ 1, 1.34 for F ≥ 2, 1.61 for F ≥ 3 and 2.00 m/s for F4. 
Concerning the comparison between ARFI and TE, this 
study found that the AUROCs were 0.709 vs. 0.902 (P = 
0.006) for F ≥ 1; 0.851 vs. 0.941 (P = 0.022) for F ≥ 2; 0.869 
vs. 0.926 (P = 0.153) for F ≥ 3; and 0.911 vs. 0.945 (P = 0.331) 
for F4. Fierbinţeanu-Braticevici, et al. (20) compared ARFI 
elastography, APRI index and FibroMax in a consecutive 
series of 74 patients who underwent LB for HCV chronic 
hepatitis  and  showed  that  the  diagnostic  accuracy  of 
ARFI elastography, expressed as AUROC had a validity of 
90.2% (95% CI: 83.1%–97.2%, P < 0.001) for the diagnosis of 
significant fibrosis (F ≥ 2). Also ARFI sonoelastography 
performed better for F3 or F4 fibrosis (AUROC = 0.993; 
95%  CI:  0.979–1).  On  the  other  hand,  in  the  study  by 
Takahashi, et al. (32) the AUROC curves were 0.94 (95% CI: 
0.87–0.99) for F2-F4, 0.94 (95% CI: 0.88–0.99) for F3-F4 and 
0.96 (95% CI: 0.91–1.01) for F4. The cut-off values of the 
shear wave velocity were as follows: > 1.34 m/s for F2-F4 
(Se of 91.4%, Sp of 80%); > 1.44 m/s for F3-F4 (Se of 96.2%, 
Sp  of  79.3%);  and  >  1.80  m/s  for  F4  (Se  of  94.1%,  Sp  of 
86.8%). The studies that we presented (18-20, 32), together 
with  the  present  study  showed  that  there  is  a  strong 
correlation  between  histological  fibrosis  and  ARFI 
measurements, also that the best performances of this 
method  are  for  the  prediction  of  severe  fibrosis  and 
cirrhosis  and  that  ARFI  is  not  better  than  TE  for  the 
evaluation of liver stiffness. Therefore, the use of ARFI 
measurements  could  be  an  advantage,  being  a  “real-
time” evaluation of LS. It can be also used in patients in 
which  valid  measurements  of  LS  by  TE  could  not  be 
obtained (since the location of ARFI measurement can 
be chosen under direct ultrasound guidance), and also 
in patients with ascites. Also, ARFI is a rapid method for 
the assessment of liver fibrosis, totally free of adverse 
events,  comfortable  for  both  the  patient  and  the 
examiner  (with  a  mean  duration  of  approximately  5 
minutes). So, immediately after an ultrasound evaluation 
of  the  liver,  ARFI  measurements  can  be  done  so  that 
information regarding the severity of liver fibrosis are 
available  on  the  spot,  without  having  to  buy  another 
machine such as the FibroScan, which is quite expensive 
(around 80,000 Euros). 
Our  study  demonstrates  that,  at  the  present  time, 
LS  evaluation  by  means  of  ARFI  is  not  superior  to  TE 
(FibroScan) for the assessment of liver fibrosis. Also, there 
is a strong correlation between histological fibrosis and 
ARFI measurements. The best performance of this method 
was shown to be for the prediction of severe fibrosis and 
cirrhosis. Another advantage of ARFI is probably the fact 
that this system is integrated in an ultrasound machine, 
which already exist in some ultrasound departments.
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